Search

Your search keyword '"Lynne A. Wolfe"' showing total 102 results

Search Constraints

Start Over You searched for: Author "Lynne A. Wolfe" Remove constraint Author: "Lynne A. Wolfe"
102 results on '"Lynne A. Wolfe"'

Search Results

1. Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up

2. Deficiency in the endocytic adaptor proteins PHETA1/2 impairs renal and craniofacial development

3. Defining Disease, Diagnosis, and Translational Medicine within a Homeostatic Perturbation Paradigm: The National Institutes of Health Undiagnosed Diseases Program Experience

4. Elevated oxysterol and N-palmitoyl-O-phosphocholineserine levels in congenital disorders of glycosylation

5. Novel CUL3 Variant Causing Familial Hyperkalemic Hypertension Impairs Regulation and Function of Ubiquitin Ligase Activity

6. Novel

7. Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11

8. A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder

9. Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

10. Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases

11. Compound heterozygous KCTD7 variants in progressive myoclonus epilepsy

12. A concurrent dual analysis of genomic data augments diagnoses: Experiences of 2 clinical sites in the Undiagnosed Diseases Network

13. One is the loneliest number: genotypic matchmaking using the electronic health record

14. Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science

15. Predominant and novel de novo variants in 29 individuals with <scp> ALG13 </scp> deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions

16. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder

17. Mutations in <scp>GET4</scp> disrupt the transmembrane domain recognition complex pathway

18. De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation

19. Lessons learned from 40 novel PIGA patients and a review of the literature

20. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease

22. Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy

23. Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification

24. Arrest of Fetal Brain Development in ALG11-Congenital Disorder of Glycosylation

25. Glycomics in rare diseases: from diagnosis tomechanism

26. Expanding the Spectrum of BAF-Related Disorders: De Novo Variants in SMARCC2 Cause a Syndrome with Intellectual Disability and Developmental Delay

27. Compound heterozygous

28. An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

29. Disorders Affecting Glycosylation

30. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

31. Forkhead box R1-mediated stress response linked to a case of human microcephaly and brain atrophy

32. Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy

33. Disease Models & Mechanisms

34. A novel frameshift mutation in SOX10 causes Waardenburg syndrome with peripheral demyelinating neuropathy, visual impairment and the absence of Hirschsprung disease

35. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling

36. Early infantile-onset epileptic encephalopathy 28 due to a homozygous microdeletion involving the WWOX gene in a region of uniparental disomy

37. A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation

38. Urine oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency

39. A recurrent de novo missense mutation in UBTF causes developmental neuroregression

40. FOXR1 regulates stress response pathways and is necessary for proper brain development

41. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

42. Correction: Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

43. The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease

44. A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by Infantile Epilepsy, Cataracts, and Profound Developmental Delay

45. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

46. De Novo Pathogenic Variants in N-cadherin Cause a Syndromic Neurodevelopmental Disorder with Corpus Callosum, Axon, Cardiac, Ocular, and Genital Defects

47. Deficiency in the endocytic adaptor protein PHETA1/2 impairs renal and craniofacial development

48. De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas, Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia

49. SLC35A2-CDG: Functional Characterization, Expanded Molecular, Clinical, and Biochemical Phenotypes of 30 Unreported Individuals

50. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells

Catalog

Books, media, physical & digital resources